Vaccines (Sep 2024)

Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study

  • Débora Cerqueira Calderaro,
  • Valéria Valim,
  • Gilda Aparecida Ferreira,
  • Ketty Lysie Libardi Lira Machado,
  • Priscila Dias Cardoso Ribeiro,
  • Sandra Lúcia Euzébio Ribeiro,
  • Natalia Sarzi Sartori,
  • Rodrigo Poubel Vieira de Rezende,
  • Ana Karla Guedes de Melo,
  • Vitor Alves Cruz,
  • Adah Sophia Rodrigues Vieira,
  • Adriana Maria Kakehasi,
  • Aline Teixeira de Landa,
  • Ana Paula Neves Burian,
  • Flávia Maria Matos Melo Campos Peixoto,
  • Camila Maria Paiva França Telles,
  • Rafaela Cavalheiro do Espírito Santo,
  • Katia Lino Baptista,
  • Yasmin Gurtler Pinheiro de Oliveira,
  • Vanessa de Oliveira Magalhães,
  • Raquel Lima de Lima,
  • Erika Biegelmeyer,
  • Pietra Zava Lorencini,
  • Andréa Teixeira-Carvalho,
  • Edgard Torres dos Reis-Neto,
  • Emília Inoue Sato,
  • Marcelo de Medeiros Pinheiro,
  • Odirlei André Monticielo,
  • Viviane Angelina de Souza,
  • Ricardo Machado Xavier,
  • Gecilmara Salviato Pileggi

DOI
https://doi.org/10.3390/vaccines12091031
Journal volume & issue
Vol. 12, no. 9
p. 1031

Abstract

Read online

Breakthrough COVID-19 (occurring in fully vaccinated people) has been described. Data on its characteristics among immune-mediated rheumatic disease (IMRD) patients are scarce. This study describes breakthrough COVID-19 occurring in IMRD patients participating in the SAFER-study, a Brazilian multicentric cohort evaluating the safety, effectiveness, and immunogenicity of SARS-CoV-2 vaccines in patients with autoimmune diseases. A descriptive analysis of the population and a binary logistic regression model were performed to evaluate the predictors of COVID-19-related hospitalization. A p-value p = 0.002) and treatment with corticosteroids (OR: 2.94; CI: 1.02–8.49; p = 0.0043) were associated with higher odds of hospitalization, while increasing the number of vaccine doses was protective (OR: 0.37; CI: 0.15–0.9; p = 0.032). These findings, along with previous reassuring results about the safety of the COVID-19 vaccines, argue in favor of booster vaccination in IMRD patients.

Keywords